Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Interstitial pneumonia with autoimmune features: a new classification still on the move.

Cavagna L, Gonzalez Gay MA, Allanore Y, Matucci-Cerinic M.

Eur Respir Rev. 2018 Jun 27;27(148). pii: 180047. doi: 10.1183/16000617.0047-2018. Print 2018 Jun 30. No abstract available.

2.

Consideration of Antisynthetase Syndrome Features in Classifying Patients as Having Idiopathic Inflammatory Myopathy: Comment on the Article by Lundberg et al.

Castañeda S, Cavagna L, González-Gay MA; American and European Network of Antisynthetase Syndrome Collaborative Group.

Arthritis Rheumatol. 2018 Jun;70(6):975-976. doi: 10.1002/art.40478. Epub 2018 Apr 29. No abstract available.

PMID:
29513937
3.

New Criteria Needed for Antisynthetase Syndrome.

Castañeda S, Cavagna L, González-Gay MA.

JAMA Neurol. 2018 Feb 1;75(2):258-259. doi: 10.1001/jamaneurol.2017.3872. No abstract available.

PMID:
29255888
4.

One year in review 2017: idiopathic inflammatory myopathies.

Barsotti S, Bruni C, Cometi L, Valentini V, Cioffi E, Neri R, Cavagna L.

Clin Exp Rheumatol. 2017 Nov-Dec;35(6):875-884. Epub 2017 Nov 29. Review.

PMID:
29185960
5.

Brief Report: Validation of a Definition of Flare in Patients With Established Gout.

Gaffo AL, Dalbeth N, Saag KG, Singh JA, Rahn EJ, Mudano AS, Chen YH, Lin CT, Bourke S, Louthrenoo W, Vazquez-Mellado J, Hernández-Llinas H, Neogi T, Vargas-Santos AB, da Rocha Castelar-Pinheiro G, Amorim RBC, Uhlig T, Hammer HB, Eliseev M, Perez-Ruiz F, Cavagna L, McCarthy GM, Stamp LK, Gerritsen M, Fana V, Sivera F, Taylor W.

Arthritis Rheumatol. 2018 Mar;70(3):462-467. doi: 10.1002/art.40381. Epub 2018 Feb 6.

PMID:
29161469
6.

Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria.

Cavagna L, Castañeda S, Sciré C, Gonzalez-Gay MA; AENEAS Collaborative Group Members.

Ann Rheum Dis. 2018 Aug;77(8):e50. doi: 10.1136/annrheumdis-2017-212368. Epub 2017 Sep 25. No abstract available.

PMID:
28970214
7.

Clinical spectrum of anti-Jo-1-associated disease.

Monti S, Montecucco C, Cavagna L.

Curr Opin Rheumatol. 2017 Nov;29(6):612-617. doi: 10.1097/BOR.0000000000000434. Review.

PMID:
28796005
8.

How I treat idiopathic patients with inflammatory myopathies in the clinical practice.

Cavagna L, Monti S, Caporali R, Gatto M, Iaccarino L, Doria A.

Autoimmun Rev. 2017 Oct;16(10):999-1007. doi: 10.1016/j.autrev.2017.07.016. Epub 2017 Aug 2. Review.

PMID:
28778704
9.

Timing of onset affects arthritis presentation pattern in antisyntethase syndrome.

González-Gay MA, Montecucco C, Selva-O'Callaghan A, Trallero-Araguas E, Molberg O, Andersson H, Rojas-Serrano J, Perez-Roman DI, Bauhammer J, Fiehn C, Neri R, Barsotti S, Lorenz HM, Doria A, Ghirardello A, Iannone F, Giannini M, Franceschini F, Cavazzana I, Triantafyllias K, Benucci M, Infantino M, Manfredi M, Conti F, Schwarting A, Sebastiani G, Iuliano A, Emmi G, Silvestri E, Govoni M, Scirè CA, Furini F, Lopez-Longo FJ, Martínez-Barrio J, Sebastiani M, Manfredi A, Bachiller-Corral J, Sifuentes Giraldo WA, Cimmino MA, Cosso C, Belotti Masserini A, Cagnotto G, Codullo V, Romano M, Paolazzi G, Pellerito R, Saketkoo LA, Ortego-Centeno N, Quartuccio L, Batticciotto A, Bartoloni Bocci E, Gerli R, Specker C, Bravi E, Selmi C, Parisi S, Salaffi F, Meloni F, Marchioni E, Pesci A, Dei G, Confalonieri M, Tomietto P, Nuno L, Bonella F, Pipitone N, Mera-Valera A, Perez-Gomez N, Gerzeli S, Lopez-Mejias R, Matos-Costa CJ, Pereira da Silva JA, Cifrian J, Alpini C, Olivieri I, Blázquez Cañamero MÁ, Rodriguez Cambrón AB, Castañeda S, Cavagna L; AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group.

Clin Exp Rheumatol. 2018 Jan-Feb;36(1):44-49. Epub 2017 Jul 26.

10.

Combined interventional sialendoscopy and intraductal steroid therapy for recurrent sialadenitis in Sjögren's syndrome: Results of a pilot monocentric trial.

Capaccio P, Canzi P, Torretta S, Rossi V, Benazzo M, Bossi A, Vitali C, Cavagna L, Pignataro L.

Clin Otolaryngol. 2018 Feb;43(1):96-102. doi: 10.1111/coa.12911. Epub 2017 Jun 26.

PMID:
28585263
11.

Clinical spectrum time course of interstitial pneumonia with autoimmune features in patients positive for antisynthetase antibodies.

Scirè CA, Gonzalez-Gay MA, Selva-O'Callaghan A, Cavagna L.

Respir Med. 2017 Nov;132:265-266. doi: 10.1016/j.rmed.2017.03.028. Epub 2017 Mar 31. No abstract available.

PMID:
28385573
12.

Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study.

Bartoloni E, Gonzalez-Gay MA, Scirè C, Castaneda S, Gerli R, Lopez-Longo FJ, Martinez-Barrio J, Govoni M, Furini F, Pina T, Iannone F, Giannini M, Nuño L, Quartuccio L, Ortego-Centeno N, Alunno A, Specker C, Montecucco C, Triantafyllias K, Balduzzi S, Sifuentes-Giraldo WA, Paolazzi G, Bravi E, Schwarting A, Pellerito R, Russo A, Selmi C, Saketkoo LA, Fusaro E, Parisi S, Pipitone N, Franceschini F, Cavazzana I, Neri R, Barsotti S, Codullo V, Cavagna L.

Autoimmun Rev. 2017 Mar;16(3):253-257. doi: 10.1016/j.autrev.2017.01.008. Epub 2017 Jan 29. Review.

PMID:
28147261
13.

Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard.

Dalbeth N, Schumacher HR, Fransen J, Neogi T, Jansen TL, Brown M, Louthrenoo W, Vazquez-Mellado J, Eliseev M, McCarthy G, Stamp LK, Perez-Ruiz F, Sivera F, Ea HK, Gerritsen M, Scire CA, Cavagna L, Lin C, Chou YY, Tausche AK, da Rocha Castelar-Pinheiro G, Janssen M, Chen JH, Cimmino MA, Uhlig T, Taylor WJ.

Arthritis Care Res (Hoboken). 2016 Dec;68(12):1894-1898. doi: 10.1002/acr.22896. Epub 2016 Oct 28.

14.

Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard.

Ogdie A, Taylor WJ, Neogi T, Fransen J, Jansen TL, Schumacher HR, Louthrenoo W, Vazquez-Mellado J, Eliseev M, McCarthy G, Stamp LK, Perez-Ruiz F, Sivera F, Ea HK, Gerritsen M, Cagnotto G, Cavagna L, Lin C, Chou YY, Tausche AK, Lima Gomes Ochtrop M, Janssen M, Chen JH, Slot O, Lazovskis J, White D, Cimmino MA, Uhlig T, Dalbeth N.

Arthritis Rheumatol. 2017 Feb;69(2):429-438. doi: 10.1002/art.39959.

15.

Undiagnosed connective tissue diseases: High prevalence in pulmonary arterial hypertension patients.

Cavagna L, Codullo V, Ghio S, Scirè CA, Guzzafame E, Scelsi L, Rossi S, Montecucco C, Caporali R.

Medicine (Baltimore). 2016 Sep;95(39):e4827. doi: 10.1097/MD.0000000000004827.

16.

Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group.

Cavagna L, Nuño L, Scirè CA, Govoni M, Longo FJ, Franceschini F, Neri R, Castañeda S, Sifuentes Giraldo WA, Caporali R, Iannone F, Fusaro E, Paolazzi G, Pellerito R, Schwarting A, Saketkoo LA, Ortego-Centeno N, Quartuccio L, Bartoloni E, Specker C, Pina Murcia T, La Corte R, Furini F, Foschi V, Bachiller Corral J, Airò P, Cavazzana I, Martínez-Barrio J, Hinojosa M, Giannini M, Barsotti S, Menke J, Triantafyllias K, Vitetta R, Russo A, Bogliolo L, Bajocchi G, Bravi E, Barausse G, Bortolotti R, Selmi C, Parisi S, Salaffi F, Montecucco C, González-Gay MA; AENEAS (American and European NEtwork of Antisynthetase Syndrome) Collaborative Group.

Clin Rev Allergy Immunol. 2017 Feb;52(1):71-80. doi: 10.1007/s12016-016-8528-9. Review.

PMID:
26782036
17.

Diagnostic Arthrocentesis for Suspicion of Gout Is Safe and Well Tolerated.

Taylor WJ, Fransen J, Dalbeth N, Neogi T, Ralph Schumacher H, Brown M, Louthrenoo W, Vazquez-Mellado J, Eliseev M, McCarthy G, Stamp LK, Perez-Ruiz F, Sivera F, Ea HK, Gerritsen M, Scire CA, Cavagna L, Lin C, Chou YY, Tausche AK, da Rocha Castelar-Pinheiro G, Janssen M, Chen JH, Slot O, Cimmino M, Uhlig T, Jansen TL.

J Rheumatol. 2016 Jan;43(1):150-3. doi: 10.3899/jrheum.150684. Epub 2015 Dec 1.

PMID:
26628602
18.

Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter Study.

Cavagna L, Nuño L, Scirè CA, Govoni M, Longo FJ, Franceschini F, Neri R, Castañeda S, Sifuentes Giraldo WA, Caporali R, Iannone F, Fusaro E, Paolazzi G, Pellerito R, Schwarting A, Saketkoo LA, Ortego-Centeno N, Quartuccio L, Bartoloni E, Specker C, Murcia TP, La Corte R, Furini F, Foschi V, Corral JB, Airò P, Cavazzana I, Martínez-Barrio J, Hinojosa M, Giannini M, Barsotti S, Menke J, Triantafyllias K, Vitetta R, Russo A, Bajocchi G, Bravi E, Barausse G, Bortolotti R, Selmi C, Parisi S, Montecucco C, González-Gay MA; AENEAS (American, European NEtwork of Antisynthetase Syndrome) collaborative group.

Medicine (Baltimore). 2015 Aug;94(32):e1144. doi: 10.1097/MD.0000000000001144.

19.

Genetics and novel aspects of therapies in systemic lupus erythematosus.

Relle M, Weinmann-Menke J, Scorletti E, Cavagna L, Schwarting A.

Autoimmun Rev. 2015 Nov;14(11):1005-18. doi: 10.1016/j.autrev.2015.07.003. Epub 2015 Jul 9. Review.

PMID:
26164648
20.

Multi-antibody composition in lupus nephritis: isotype and antigen specificity make the difference.

Bonanni A, Vaglio A, Bruschi M, Sinico RA, Cavagna L, Moroni G, Franceschini F, Allegri L, Pratesi F, Migliorini P, Candiano G, Pesce G, Ravelli A, Puppo F, Martini A, Tincani A, Ghiggeri GM.

Autoimmun Rev. 2015 Aug;14(8):692-702. doi: 10.1016/j.autrev.2015.04.004. Epub 2015 Apr 14. Review.

PMID:
25888464
21.

Study for Updated Gout Classification Criteria: Identification of Features to Classify Gout.

Taylor WJ, Fransen J, Jansen TL, Dalbeth N, Schumacher HR, Brown M, Louthrenoo W, Vazquez-Mellado J, Eliseev M, McCarthy G, Stamp LK, Perez-Ruiz F, Sivera F, Ea HK, Gerritsen M, Scire C, Cavagna L, Lin C, Chou YY, Tausche AK, Vargas-Santos AB, Janssen M, Chen JH, Slot O, Cimmino MA, Uhlig T, Neogi T.

Arthritis Care Res (Hoboken). 2015 Sep;67(9):1304-15. doi: 10.1002/acr.22585.

22.

Performance of classification criteria for gout in early and established disease.

Taylor WJ, Fransen J, Dalbeth N, Neogi T, Schumacher HR, Brown M, Louthrenoo W, Vazquez-Mellado J, Eliseev M, McCarthy G, Stamp LK, Perez-Ruiz F, Sivera F, Ea HK, Gerritsen M, Scire C, Cavagna L, Lin C, Chou YY, Tausche AK, da Rocha Castelar-Pinheiro G, Janssen M, Chen JH, Slot O, Cimmino M, Uhlig T, Jansen TL.

Ann Rheum Dis. 2016 Jan;75(1):178-82. doi: 10.1136/annrheumdis-2014-206364. Epub 2014 Oct 28.

PMID:
25351521
23.

Biotechnological drugs: the breakthrough in autoimmune rheumatic conditions.

Cavagna L, Saketkoo LA, Schwarting A, Caporali R.

Biomed Res Int. 2014;2014:481973. doi: 10.1155/2014/481973. Epub 2014 Aug 10. No abstract available.

24.

Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry.

Filippini M, Bazzani C, Atzeni F, Sarzi Puttini P, Marchesoni A, Favalli EG, Caporali R, Cavagna L, Gorla R.

Biomed Res Int. 2014;2014:416892. doi: 10.1155/2014/416892. Epub 2014 Jul 6.

25.

Colony-stimulating factor-1: a potential biomarker for lupus nephritis.

Menke J, Amann K, Cavagna L, Blettner M, Weinmann A, Schwarting A, Kelley VR.

J Am Soc Nephrol. 2015 Feb;26(2):379-89. doi: 10.1681/ASN.2013121356. Epub 2014 Jul 10.

26.

A hyper-ferritinemia syndrome evolving in recurrent macrophage activation syndrome, as an onset of amyopathic juvenile dermatomyositis: a challenging clinical case in light of the current diagnostic criteria.

Poddighe D, Cavagna L, Brazzelli V, Bruni P, Marseglia GL.

Autoimmun Rev. 2014 Nov;13(11):1142-8. doi: 10.1016/j.autrev.2014.05.009. Epub 2014 May 29. Review.

PMID:
24879966
27.

The emerging role of biotechnological drugs in the treatment of gout.

Cavagna L, Taylor WJ.

Biomed Res Int. 2014;2014:264859. doi: 10.1155/2014/264859. Epub 2014 Apr 16. Review.

28.

The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy.

Ingrasciotta Y, Sultana J, Giorgianni F, Caputi AP, Arcoraci V, Tari DU, Linguiti C, Perrotta M, Nucita A, Pellegrini F, Fontana A, Cavagna L, Santoro D, Trifirò G.

PLoS One. 2014 Feb 18;9(2):e89072. doi: 10.1371/journal.pone.0089072. eCollection 2014.

29.

[New perspectives in the classification and treatment of systemic lupus erythematosus: the central role of kidney involvement].

Cavagna L, Scorletti E, Romano M, Cagnotto G, Caporali R.

G Ital Nefrol. 2013 Jul-Aug;30(4). pii: gin/30.4.9. Italian.

PMID:
24403199
30.

Spinal hemorrhage in eosinophilic granulomatosis with polyangiitis (Churg-Strauss).

Diamanti L, Berzero G, Bini P, Ravaglia S, Rognone E, Cavagna L, Marchioni E.

J Neurol. 2014 Feb;261(2):438-40. doi: 10.1007/s00415-013-7217-3. Epub 2013 Dec 25. No abstract available.

PMID:
24368404
31.

The multifaceted aspects of interstitial lung disease in rheumatoid arthritis.

Cavagna L, Monti S, Grosso V, Boffini N, Scorletti E, Crepaldi G, Caporali R.

Biomed Res Int. 2013;2013:759760. doi: 10.1155/2013/759760. Epub 2013 Sep 25. Review.

32.

Chromosomally integrated human herpesvirus 6 in a patient with systemic lupus erythematosus.

Cavagna L, Scorletti E, Inverardi F, Baldanti F, Campanini G, Montecucco C, Caporali R.

Lupus. 2013 Sep;22(10):1087-8. doi: 10.1177/0961203313498794. Epub 2013 Jul 24. No abstract available.

PMID:
23884984
33.

WITHDRAWN: Abatacept as a first-line biological therapy.

Caporali R, Bugatti S, Cavagna L, Antivalle M, Atzeni F, Puttini PS.

Autoimmun Rev. 2013 Jun 24. pii: S1568-9972(13)00114-6. doi: 10.1016/j.autrev.2013.06.010. [Epub ahead of print]

PMID:
23806564
34.

Long-term safety of abatacept in patients with rheumatoid arthritis.

Atzeni F, Sarzi-Puttini P, Mutti A, Bugatti S, Cavagna L, Caporali R.

Autoimmun Rev. 2013 Oct;12(12):1115-7. doi: 10.1016/j.autrev.2013.06.011. Epub 2013 Jun 22. Review.

PMID:
23800448
35.

Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment?

Caporali R, Bugatti S, Cavagna L, Antivalle M, Sarzi-Puttini P.

Autoimmun Rev. 2014 Jan;13(1):49-53. doi: 10.1016/j.autrev.2013.06.008. Epub 2013 Jun 15. Review.

PMID:
23777823
36.

Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores.

Atzeni F, Bongiovanni S, Marchesoni A, Filippini M, Caporali R, Gorla R, Cavagna L, Favalli EG, Saccardo F, Sarzi-Puttini P.

Joint Bone Spine. 2014 Jan;81(1):37-40. doi: 10.1016/j.jbspin.2013.04.005. Epub 2013 Jun 2.

PMID:
23731638
37.

Therapeutic options in anti-jo-1 antisynthetase syndrome with interstitial lung disease: comment on the article by Marie et al.

Cavagna L, Caporali R.

Arthritis Care Res (Hoboken). 2013 Sep;65(9):1548. doi: 10.1002/acr.22024. No abstract available.

38.

Overuse of prescription and OTC non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis and osteoarthritis.

Cavagna L, Caporali R, Trifiro G, Arcoraci V, Rossi S, Montecucco C.

Int J Immunopathol Pharmacol. 2013 Jan-Mar;26(1):279-81.

PMID:
23527735
39.

The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.

Quartuccio L, Fabris M, Pontarini E, Salvin S, Zabotti A, Benucci M, Manfredi M, Biasi D, Ravagnani V, Atzeni F, Sarzi-Puttini P, Morassi P, Fischetti F, Tomietto P, Bazzichi L, Saracco M, Pellerito R, Cimmino M, Schiavon F, Carraro V, Semeraro A, Caporali R, Cavagna L, Bortolotti R, Paolazzi G, Govoni M, Bombardieri S, De Vita S.

Ann Rheum Dis. 2014 Apr;73(4):716-21. doi: 10.1136/annrheumdis-2012-202435. Epub 2013 Mar 16.

PMID:
23505228
40.

Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease.

Cavagna L, Caporali R, Abdì-Alì L, Dore R, Meloni F, Montecucco C.

J Rheumatol. 2013 Apr;40(4):484-92. doi: 10.3899/jrheum.121026. Epub 2013 Feb 15.

PMID:
23418387
41.

Atherosclerosis and rheumatoid arthritis: more than a simple association.

Cavagna L, Boffini N, Cagnotto G, Inverardi F, Grosso V, Caporali R.

Mediators Inflamm. 2012;2012:147354. Epub 2012 Sep 13.

42.

Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study.

Trifirò G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M, Bianchini E, Medea G, Cricelli C, Caputi AP, Mazzaglia G.

Ann Rheum Dis. 2013 May;72(5):694-700. doi: 10.1136/annrheumdis-2011-201254. Epub 2012 Jun 26.

PMID:
22736095
43.

Sinonasal surgery in Wegener's granulomatosis: is it time to go on?

Pagella F, Canzi P, Matti E, Giourgos G, Caporali R, Cavagna L.

Laryngoscope. 2011 Dec;121(12):2717-8; author reply 2719-20. doi: 10.1002/lary.21883. Epub 2011 Sep 26. No abstract available.

PMID:
21952921
44.

Association between anti-dsDNA titre increase and thymoma relapse.

Cavagna L, Prisco E, Montecucco C, Caporali R.

Clin Exp Rheumatol. 2011 May-Jun;29(3):599-600. Epub 2011 Jun 30. No abstract available.

PMID:
21722507
45.

Pulmonary arterial hypertension in antisynthetase syndrome: comment on the article by Chatterjee and Farver.

Cavagna L, Prisco E, Montecucco C, Caporali R.

Arthritis Care Res (Hoboken). 2011 Apr;63(4):633-4; author reply 634. doi: 10.1002/acr.20392. No abstract available.

46.

Anti-Ma2/Ta antibodies in a woman with primary lateral sclerosis-like phenotype and Sjögren syndrome.

Piccolo G, Tavazzi E, Jarius S, Alfonsi E, Cavagna L, Piccolo L, Zardini E, Voltz R, Franciotta D.

Neurol Sci. 2011 Oct;32(5):915-7. doi: 10.1007/s10072-011-0510-y. Epub 2011 Mar 3.

PMID:
21369848
47.

Inappropriate exercise-induced increase in pulmonary artery pressure in patients with systemic sclerosis.

D'Alto M, Ghio S, D'Andrea A, Pazzano AS, Argiento P, Camporotondo R, Allocca F, Scelsi L, Cuomo G, Caporali R, Cavagna L, Valentini G, Calabrò R.

Heart. 2011 Jan;97(2):112-7. doi: 10.1136/hrt.2010.203471. Epub 2010 Oct 3.

PMID:
20889989
48.

Anticyclic citrullinated peptide antibodies as markers of erosive arthritis in antisynthetase syndrome.

Cavagna L, Fusetti C, Montecucco C, Caporali R.

J Rheumatol. 2010 Sep;37(9):1967; author reply 1968. doi: 10.3899/jrheum.091402. No abstract available.

PMID:
20810525
49.

The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases.

Atzeni F, Turiel M, Caporali R, Cavagna L, Tomasoni L, Sitia S, Sarzi-Puttini P.

Autoimmun Rev. 2010 Oct;9(12):835-9. doi: 10.1016/j.autrev.2010.07.018. Epub 2010 Jul 30.

PMID:
20678592
50.

Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis.

Cavagna L, Caporali R, Klersy C, Ghio S, Albertini R, Scelsi L, Moratti R, Bonino C, Montecucco C.

J Rheumatol. 2010 Oct;37(10):2064-70. doi: 10.3899/jrheum.090997. Epub 2010 Jul 15.

PMID:
20634241

Supplemental Content

Loading ...
Support Center